文献速递妇产影像泌尿生殖技术与安全USCTMRPET

血清肿瘤标志物在卵巢癌管理中的过去、现在和未来:放射科医生指南

Past, Present, and Future of Serum Tumor Markers in Management of Ovarian Cancer: A Guide for the Radiologist.
PubMed 文献 · Radiographics · 2021-01-01

本文综述了CA-125、HE4、CA19-9和CEA等血清肿瘤标志物在卵巢癌诊断、监测和随访中的临床应用,强调CA-125联合超声是高危附件肿块的主要诊断方式,CT用于分期,MRI用于不确定病变的定性,液体活检是未来方向。

要点

  • CA-125联合超声(大附件肿块或高危特征如分隔、血流增加)是卵巢癌诊断的主要方式。
  • 不同血清标志物与卵巢癌亚型相关:CA19-9与透明细胞瘤、畸胎瘤;CEA与黏液性癌;HE4与浆液性和子宫内膜样癌。
  • CT是分期的首选方法,MRI用于超声或CT不确定的卵巢病变定性。

关键影像表现/征象

  • CA-125水平在多种卵巢癌中可升高,包括上皮性肿瘤、癌肉瘤、畸胎瘤和继发性卵巢恶性肿瘤。
  • CA19-9升高与透明细胞瘤、畸胎瘤和继发性恶性肿瘤相关。
  • CEA最常与黏液性卵巢癌相关。
  • HE4越来越多用于识别特定亚型上皮性卵巢癌,尤其是浆液性和子宫内膜样肿瘤。
  • 超声高危特征包括大附件肿块、分隔和血流增加。

诊断标准与关键数值

  • 当前指南不推荐血清肿瘤标志物作为卵巢癌的筛查工具。
  • 诊断依赖CA-125水平与超声发现的组合。

临床应用与阅片要点

  • 放射科医生应了解不同血清标志物与卵巢癌亚型的关联,以辅助影像解读。
  • 超声发现大附件肿块或高危特征(分隔、血流增加)时应结合CA-125水平。
  • CT用于分期,MRI用于超声或CT不确定的卵巢病变定性。
  • 监测时联合PET和血清肿瘤标志物。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

The ability to accurately detect early ovarian cancer and subsequently monitor treatment response is essential to improving survival for patients with ovarian malignancies. Several serum tumor markers (STMs)-including cancer antigen 125 (CA-125), human epididymis protein 4 (HE4), cancer antigen 19-9 (CA 19-9), and carcinoembryonic antigen (CEA)-have been used as a noninvasive method of identifying ovarian cancer in conjunction with imaging. Although current guidelines do not recommend use of STMs as screening tools for ovarian cancer, these markers have clinical utility in both diagnosis and surveillance for women with ovarian cancer. CA-125 is the most commonly used STM; its level may be elevated in several types of ovarian cancer, including epithelial cell tumors, carcinosarcoma, teratomas, and secondary ovarian malignancies. An elevated level of CA 19-9 is associated with clear cell tumors, teratomas, and secondary malignancies. CEA is most commonly associated with mucinous ovarian cancers. Finally, HE4 is being increasingly used to identify certain subtypes of epithelial ovarian cancers, particularly serous and endometrioid tumors. Diagnosis of ovarian cancers relies on a combination of CA-125 levels and US findings, which include a large adnexal mass or high-risk features, including septa and increased vascularity. CT is preferred for staging and is used along with PET and STM monitoring for surveillance. Increasingly, MRI is being used to characterize ovarian lesions that are indeterminate at US or CT. The future of STM testing involves development of "liquid biopsies," in which plasma samples are analyzed for evidence of tumors, including circulating tumor DNA or tumor cells and tumor micro-RNA. When combined with traditional imaging techniques, liquid biopsies may lead to earlier diagnosis and improved survival. An invited commentary by Shinagare is available online. ©RSNA, 2021.

来源:Radiographics,查看原文。版权归原作者所有。

引用

  1. Rao S, Smith DA, Guler E, et al. Past, Present, and Future of Serum Tumor Markers in Management of Ovarian Cancer: A Guide for the Radiologist. Radiographics. 2021. PMID: 34597221. doi:10.1148/rg.2021210005

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。